Guideline Lifeline
Most of the educational tools are linked to an explainer video that reviews the key updates in the relevant guidelines from the AHA, ACC, and ESC. The goal of these educational materials is to help increase understanding and uptake of the guidelines.
Watch the playlist on YouTube (opens in a new tab)
17 Oct 2026
Covers hypertension in pregnancy, from when to start drug treatment and plan delivery to the drugs for severe hypertension. Also works through statins, DAPT after PCI, flecainide and ablation for arrhythmias, cardiac arrest, mitral stenosis before pregnancy and beta-blocker choices.
10 Oct 2026
Explains the modified WHO 2.0 risk classification, the role of CARPREG II and who needs a Pregnancy Heart Team. Also covers delivery and anticoagulation, lactation, contraindicated drugs, long QT syndrome, CPVT and peripartum cardiomyopathy.
4 Oct 2026
Answers practical questions about antiarrhythmic drugs in groups the trials left out, such as whether to stress test before flecainide or propafenone. Also covers sotalol in heart failure, dofetilide dosing gaps, washout when switching drugs and why Bazett's formula fails in atrial fibrillation.
1 Oct 2026
Covers advanced heart failure: the "I NEED HELP" criteria, INTERMACS profiles and why durable LVAD support moved to Class I. Also reviews mitral TEER, semaglutide and tirzepatide, pulmonary artery pressure monitoring and treatments for transthyretin amyloidosis.
29 Sep 2026
Explains the new heart failure terms that replaced HFmrEF and the framework of foundational, additional and interventional therapy. Also covers MRA choice, uptitration, the digoxin and vericiguat changes, diuretic response and mechanical support in cardiogenic shock.
5 Sep 2026
Explains residual inflammatory risk, how to measure it with hsCRP and when to intensify statin therapy. Also reviews low-dose colchicine in stable atherosclerosis, why it failed in acute MI, who should not take it and which drugs interact.
29 Aug 2026
Describes how the Fifth Universal Definition replaces numeric MI types 1 to 5 with primary, secondary and procedure-related MI. Also covers the new troponin thresholds after CABG and PCI, how sudden death is classified and the renaming of MINOCA.
22 Aug 2026
Reviews how to diagnose cardiac amyloidosis, including cardiac MRI, free light chain ratios and pyrophosphate scintigraphy with the Perugini scale. Also covers early clues to ATTR-CM and how tafamidis, acoramidis and vutrisiran differ.
24 Jul 2026
Covers diagnosing HFpEF with the H2FPEF, HFA-PEFF and HFpEF-ABA scores, and the conditions that mimic it. Also explains therapy choices, including finerenone over spironolactone, semaglutide or tirzepatide, and when to use or avoid ACE inhibitors, sacubitril/valsartan and beta blockers.
22 Jul 2026
Explains why the 2026 universal definition dropped numerical ejection fraction cutoffs, and how improvement, remission and recovery of heart failure differ. Also covers worsening versus decompensated heart failure and the new classification by cause.
17 May 2026
A board review lecture on the ESC 2025 guidelines for mitral valve disease. Given on 15 May 2026 in Taipei at the European Exam in Core Cardiology review course.
16 May 2026
A board review lecture on the ESC 2025 guidelines for aortic valve disease. Given on 15 May 2026 in Taipei at the European Exam in Core Cardiology review course.
15 May 2026
A board review lecture on the ESC 2025 focused update on managing dyslipidaemia. Given on 15 May 2026 in Taipei at the European Exam in Core Cardiology review course.
18 Mar 2026
Covers when to measure apoB and lipoprotein(a), how to calculate LDL-C, and how the PREVENT-ASCVD equations differ from the Pooled Cohort Equations. Also explains coronary calcium scoring for statin decisions, the new secondary prevention targets and when to add bempedoic acid, inclisiran or olezarsen.
22 Feb 2026
Explains the new 2026 classification of acute pulmonary embolism, including the respiratory modifier and normotensive shock, and how the PESI, sPESI, Hestia and CPES scores differ. Also covers anticoagulant choice, when to use lysis, catheter therapy or surgery, clot in transit and vasopressors.
20 Dec 2025
Covers key decisions in adult congenital heart disease, such as timing of pulmonary valve replacement in tetralogy of Fallot and closing an atrial septal defect with pulmonary hypertension. Also reviews Fontan liver surveillance, Eisenmenger syndrome, pregnancy and delivery, and sports.
17 Aug 2025
Covers what is new in the 2025 blood pressure guideline, including the new term for hypertensive urgency and when to use a single-pill combination. Also reviews testing for primary aldosteronism, acute blood pressure targets in a neurologic condition, dementia risk and renal denervation.
16 Apr 2025
A rapid review of mitral regurgitation and stenosis in the 2021 ESC valve guidelines. Presented at the APSC Board Review Course in Busan, Korea, as preparation for the European Exam in Core Cardiology.
16 Apr 2025
A rapid review of aortic regurgitation and stenosis in the 2021 ESC valve guidelines. Presented at the APSC Board Review Course in Busan, Korea, as preparation for the European Exam in Core Cardiology.
21 Mar 2025
Covers whether and when to revascularize non-culprit lesions in STEMI and NSTEMI, including with cardiogenic shock. Also reviews P2Y12 inhibitor choice and de-escalation, triple therapy duration after PCI, and Impella, IABP and VA-ECMO in shock.
